Vaccination against cholera and ETEC diarrhea 
and interventions to improve vaccine immune responses

Akademisk avhandling

som för avläggande av medicine doktorsexamen vid Sahlgrenska akademin vid Göteborgs universitet 
kommer att offentligen försvaras i föreläsningssal “Ragnar Sandberg”, Medicinaregatan 7A, Göteborg, 
tisdagen den 2 juni 2009, kl 9.00

av

Tanvir Ahmed, MD

Fakultetsopponent: Professor Hannah Akuffo, MTC, Karolinska Institutet, Stockholm

Avhandlingen baseras på följande arbeten:


Vaccination against cholera and ETEC diarrhea and interventions to improve vaccine immune responses

Tanvir Ahmed  
Department of Microbiology and Immunology, Institute of Biomedicine at the Sahlgrenska Academy, University of Gothenburg

Abstract

*Vibrio cholerae* O1 and enterotoxigenic *Escherichia coli* (ETEC) together account for the majority of bacterial causes of acute dehydrating diarrhea in children in Bangladesh. Vaccines should be considered as an important public health tool for prevention of these diarrheal diseases. However, a limitation for the use of vaccines in developing countries is that the efficacy and immunogenicity of vaccines, especially oral enteric vaccines, are lower in these countries than in the industrialized world. The main objectives of the thesis were to study the safety and immunogenicity of oral cholera toxin B subunit (CTB) containing inactivated whole cell ETEC and cholera vaccines in young children in a developing country and to identify possible immune modulating factors, e.g. vaccine dose, different buffer formulations, effects of breast milk withholding and zinc supplementation.

For determining optimal doses of the ETEC vaccine, we immunized 6 months to 12 year old children with full, half and quarter doses of the ETEC vaccine. Safety and immunogenicity of different vaccine doses were compared. All doses of the ETEC vaccine were found to be equally immunogenic in the older children. However, a quarter dose, although giving somewhat lower antibacterial responses than a full dose, was required for children 6-18 months to avoid reactogenicity.

For determining the safety and immunogenicity of the cholera vaccine in young children and the effect of different interventions to try to enhance immune responses, children 6-18 months of age were given two doses of the vaccine according to the standard protocol or with different modifications. In addition to analyzing antibacterial and antitoxic B-cell responses, T-cell responses were determined using a new flow cytometric technique, FASCIA. The vaccine was found to be safe and to induce both antibody and Th1 type T-cell responses. Vibriocidal antibody responses were improved by temporarily withholding breast-feeding for three hours before immunization as well as by giving 20 mg of zinc from 3 weeks prior to and one week after the second dose of vaccine. Zinc supplementation also enhanced IFN-γ responses to CTB.

Further objectives of this thesis were to analyze the immune responses to one of the most prevalent ETEC colonization factors (CFs), i.e. CS6, in patients infected with CS6-positive ETEC and to evaluate if there is an association between expression of certain Lewis blood group antigens of the host and infection by ETEC expressing different CFs. Natural infection with CS6 ETEC was found to induce robust systemic and mucosal immune responses in 70-90% of adults and children with diarrhea caused by CS6 positive ETEC strains, suggesting that CS6 could be an important immunogenic component of a new ETEC vaccine. We could also show that individuals with Le (a+b-) blood group had increased susceptibility to infection with ETEC expressing CFA/I group fimbriae.

The results of these studies give important background information regarding the possibility of inducing effective immune responses to oral inactivated enteric vaccines in young children in developing countries.

**Keywords:** *Vibrio cholerae*, ETEC, oral vaccine, CS6, CFA/I, Lewis blood group, zinc, breast feeding, T cell, B cell

**ISBN 978-91-628-7789-7**